Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Filings indexed 377 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2026-05-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings
2026-05-15 English
6-K - Enlivex Ltd. (0001596812) (Filer)
Regulatory Filings
2026-04-21 English
6-K - Enlivex Ltd. (0001596812) (Filer)
Regulatory Filings
2026-04-08 English
6-K - Enlivex Ltd. (0001596812) (Filer)
Regulatory Filings
2026-03-26 English
20-F - Enlivex Ltd. (0001596812) (Filer)
Annual Report FY 2025
2026-03-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.